Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study
The United States (US) Expanded Access Program (EAP) to coronavirus disease 2019 (COVID-19) convalescent plasma was initiated in response to the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of COVID-19. While randomized clinical trials were in var...
محفوظ في:
مواد مشابهة
-
Access to and safety of COVID-19 convalescent plasma in the United States Expanded Access Program: A national registry study
حسب: Senefeld, Jonathon W., وآخرون
منشور في: (2021) -
Program and patient characteristics for the United States Expanded Access Program to COVID-19 convalescent plasma
حسب: Senefeld, Jonathon W., وآخرون
منشور في: (2021) -
Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors
حسب: Kunze, Katie L., وآخرون
منشور في: (2021) -
Mortality in individuals treated with COVID-19 convalescent plasma varies with the geographic provenance of donors
حسب: Katie L. Kunze, وآخرون
منشور في: (2021) -
Safety Update
حسب: Michael J. Joyner, وآخرون
منشور في: (2020)